Immunotherapy / PD-1 inhibitorPhase 3 trialInvestigational
PDR001
Generic name: pembrolizumab
How it works
Blocks the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells more effectively.
Cancer types
Melanoma— All patients
Efficacy
Studies show that pembrolizumab can improve overall survival in patients with advanced melanoma, with a median overall survival of approximately 10.5 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combining Chemotherapy and Immunotherapy for Lung Cancer | Lung Cancer | observational | — | Source → |
| Testing New Treatments for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing a New Treatment for Brain Metastases from Non-small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Lung Cancer Treatment Combination | Lung Cancer | phase-3 | — | Source → |
| Testing a New Imaging Agent for Lung Cancer Treatment Response | Lung Cancer | phase-1 | — | Source → |
| Testing MQ719 with and without Pembrolizumab in Solid Tumor Cancer Patients | Melanoma | phase-1 | — | Source → |
| Testing a Combination of Vaccines and Immunotherapy for Advanced Lung and Head and Neck Cancers | Lung Cancer | phase-1 | — | Source → |
| Testing Sacituzumab Tirumotecan and Pembrolizumab in Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| EIK1001 Combination Therapy for Stage 4 Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Folfirinox and Pembrolizumab for Resectable Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Zongertinib in Combination with Chemotherapy for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| New Study Examines Treatment for Advanced Triple-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Pembrolizumab's Effectiveness in Lung Cancer Treatment | Lung Cancer | review | — | Source → |
| Testing Sitagliptin and Pembrolizumab in Advanced Cancer | Melanoma | phase-1 | — | Source → |
| Immune Checkpoint Inhibitors for Lung Cancer: Cost-Effectiveness Study | Lung Cancer | observational | Pembrolizumab demonstrated the longest median overall survival (OS) at 15.49 months in stage IV, and 34.64 months in stage III. | Source → |
| Pembrolizumab and Chemotherapy for Early-stage Triple-negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Evaluating a Combination Treatment for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Pembrolizumab and Paclitaxel for Recurring Triple-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Study Examines Niraparib-Plus-Pembrolizumab for Lung Cancer Maintenance Therapy | Lung Cancer | phase-3 | The median progression-free survival was 5.55 months for both treatment arms. | Source → |
| Testing ILKN421H and Pembrolizumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Immunotherapy Options for Colorectal Cancer | Colorectal Cancer | review | Pembrolizumab has a well-characterized long-term safety profile and superior progression-free and overall survival versus chemotherapy. | Source → |
| Testing a New Treatment for Advanced Solid Tumors | Breast Cancer | phase-1 | — | Source → |
| Managing Skin Reactions to Cancer Treatment with Methotrexate | Melanoma | observational | — | Source → |
| Testing New Treatment for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Pembrolizumab in Black Patients with Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Pembrolizumab Rechallenge Shows Promise in Lung Cancer | Lung Cancer | observational | — | Source → |
| Testing Fianlimab and Cemiplimab for Melanoma Prevention | Melanoma | phase-3 | — | Source → |
| Testing a Vaccine and Medicine Combination for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Immunotherapy Helps Patient with Advanced Pancreatic Cancer | Pancreatic Cancer | observational | — | Source → |
| Testing ASTX660 and Pembrolizumab in Advanced Cancer Patients | Breast Cancer | phase-1 | — | Source → |
| Testing a New Combination Treatment for Metastatic Melanoma | Melanoma | phase-1 | — | Source → |
| Testing Combination Therapies for Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Rare Eye Inflammation Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Testing NEO-201 in Combination with Pembrolizumab for Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Testing New Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Pancreatic Cancer Trial Examines Combination Treatment | Pancreatic Cancer | phase-2 | — | Source → |
| Pembrolizumab for Advanced Breast Cancer: A Phase 2 Clinical Trial | Breast Cancer | phase-2 | — | Source → |
| Testing Focused Ultrasound to Open Blood-Brain Barrier for Lung Cancer Brain Metastases | Lung Cancer | phase-3 | — | Source → |
| Combining Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Fecal Microbiota Transplant and Anti-PD-1 Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| New Lung Cancer Treatment Shows Promise | Lung Cancer | preclinical | Six patients (54.5%) achieved pathological complete response. | Source → |
| Immune Checkpoint Inhibitors for Lung Cancer: Cost-Effectiveness Study | Lung Cancer | observational | Pembrolizumab demonstrated the longest median overall survival (OS) at 15.49 months in stage IV, and 34.64 months in stage III. | Source → |
| Testing Pembrolizumab for Lung Cancer Treatment | Lung Cancer | phase-2 | — | Source → |
| Pembrolizumab Study for Advanced Solid Tumors | Breast Cancer | phase-2 | — | Source → |
| Pembrolizumab vs. Observation in Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Rare Side Effect of Cancer Treatment: Muscle Weakness Linked to Pembrolizumab | Lung Cancer | review | — | Source → |
| Cryotherapy May Enhance Lung Cancer Treatment | Lung Cancer | phase-2 | — | Source → |
| Testing a New Combination Therapy for Advanced Solid Tumors | Ovarian Cancer | phase-1 | — | Source → |
| Investigating Petosemtamab for Metastatic Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Pembrolizumab Alone or With Chemotherapy for Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing a New Cancer Treatment Combination in Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Pembrolizumab and Chemotherapy Combination for Advanced Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Rare Cancer Patient Experiences Two Types of Joint Pain | Lung Cancer | observational | — | Source → |
| Comparing Treatments for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing a Combination Therapy for Early-stage Triple-negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Pembrolizumab and Cryoablation for Metastatic Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Monitoring Blood Markers in Lung Cancer Patients on Immunotherapy | Lung Cancer | phase-2 | — | Source → |
| Pembrolizumab May Help Treat Rare Breast Cancer | Breast Cancer | observational | — | Source → |
| Pembrolizumab and Chemotherapy Combination Study for Stage IV Non-Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Combining Gut Bacteria and Immunotherapy Shows Promise in Cancer Treatment | Lung Cancer | phase-1 | In ICI-naïve NSCLC (n=12) with programmed death-ligand 1 (PD-L1) >50%, the overall response rate (ORR) and disease control rate (DCR) were 58% and 75%, respectively. | Source → |
| Combination Therapy for Ovarian Cancer: A Phase II Clinical Trial | Ovarian Cancer | phase-2 | — | Source → |
| Testing Combination Immunotherapy for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Pembrolizumab Shows Promise in Treating Advanced Anal Cancer | Colorectal Cancer | observational | The objective response rate was 13.5%, with two complete and three partial responses. | Source → |
| Talabostat and Pembrolizumab Show Some Effectiveness in Treating Aggressive Prostate Cancer | Prostate Cancer | phase-2 | The composite response rate was 20% (95% CI 7.7% to 38.6%) and the objective response rate was 13% (95% CI 3.8% to 30.7%). | Source → |
| Combination Therapy for Metastatic Melanoma and Renal Cell Carcinoma | Melanoma | phase-2 | — | Source → |
| Pembrolizumab-Chemotherapy for Lung Cancer: Real-World Study in Serbia | Lung Cancer | observational | Median progression-free survival was 7.03 months (95% CI, 4.81-9.26). | Source → |
| Melanoma Treatment Trial Investigates Combination Therapy | Melanoma | phase-2 | — | Source → |
| Olaparib and Pembrolizumab in Breast Cancer Treatment | Breast Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Lung Cancer: A Phase 3 Clinical Trial | Lung Cancer | phase-3 | — | Source → |
| Evaluating a New Treatment Combination for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Longer Pembrolizumab Therapy May Improve Survival in Advanced Melanoma | Melanoma | observational | Long-term therapy significantly reduced overall mortality (HR = 0.41, 95% CI: 0.27-0.62) compared with short-term therapy. | Source → |
| Pembrolizumab for Metastatic Prostate Cancer After Enzalutamide Treatment | Prostate Cancer | phase-2 | — | Source → |
| Testing a New Combination Therapy for Advanced Non-small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Ovarian Cancer Treatment Trial Investigates New Combination Therapy | Ovarian Cancer | phase-1 | — | Source → |
| Testing Pembrolizumab in Children with Advanced Cancer | Melanoma | phase-1 | — | Source → |
| Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Melanoma Treatment Trial: Intismeran Autogene and Pembrolizumab | Melanoma | phase-2 | — | Source → |
| Pembrolizumab Helps Patient with Advanced Colon Cancer | Colorectal Cancer | observational | — | Source → |
| Immunochemotherapy Impact on Surgery Outcomes in Early Triple-Negative Breast Cancer | Breast Cancer | observational | — | Source → |
| New Study Examines Blood Test and Protein Marker in Lung Cancer Treatment | Lung Cancer | observational | Low baseline SII was significantly associated with superior progression-free survival (PFS) (p = 0.031) and overall survival (OS) (p = 0.004). | Source → |
| Rare Complications from Long-Term Cancer Treatment | Lung Cancer | observational | — | Source → |
| Rare Side Effect of Cancer Treatment Managed with New Approach | Melanoma | observational | — | Source → |
| Comparing Liver Safety of Two Cancer Treatments | Lung Cancer | observational | — | Source → |
| Evaluating a New Treatment for High-Risk Melanoma | Melanoma | phase-2 | — | Source → |
| Melanoma Treatment Trial: Intismeran Autogene and Pembrolizumab | Melanoma | phase-3 | — | Source → |
| Pembrolizumab Improves Survival in Early-Stage Triple-Negative Breast Cancer | Breast Cancer | phase-3 | The hazard ratios for event-free survival were 0.70 (0.38-1.31), 0.92 (0.39-2.20), 0.52 (0.32-0.82), and 1.24 (0.69-2.23) across different residual cancer burden categories. | Source → |
| Pembrolizumab Dosage Study in Lung Cancer Patients | Lung Cancer | observational | The overall survival rate was 36.6% in the fixed-dose group and 37.7% in the weight-based dose group. | Source → |
| Immunotherapy Shows Promise for Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| New Options for Lung Cancer Treatment After Surgery | Lung Cancer | phase-3 | Improved disease-free survival and, in case of PD-L1 at least 50%, also improved overall survival for atezolizumab compared to best supportive care. | Source → |
| Pembrolizumab in Prostate Cancer: New Combination Therapies Show Promise | Prostate Cancer | review | — | Source → |
| Pembrolizumab Therapy and Cardiovascular Risks | Melanoma | review | — | Source → |
| Rare Skin Reaction Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Diabetes May Affect Efficacy of Cancer Treatment | Lung Cancer | observational | Patients with diabetes had a median progression-free survival of 5.9 months and overall survival of 12 months, compared to 7.1 months and 21 months for those without diabetes. | Source → |
| Long-term Survival Benefit of Pembrolizumab in Advanced Melanoma | Melanoma | phase-3 | Median overall survival was 32.7 months for pembrolizumab versus 15.9 months for ipilimumab. | Source → |
| Testing Immunotherapy Before Surgery for Colon Cancer | Colorectal Cancer | phase-2 | — | Source → |
| New Cancer Treatment Tested in Ovarian Cancer Patients | Ovarian Cancer | phase-3 | — | Source → |
| mRNA Vaccine May Help Prevent Melanoma Recurrence | Melanoma | phase-2 | — | Source → |
| Pembrolizumab Shows Promise for Inoperable Desmoplastic Melanoma | Melanoma | phase-2 | — | Source → |
| Rare Kidney Damage Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
| Pembrolizumab as Adjuvant Treatment for Melanoma: Cost-Effectiveness Study | Melanoma | phase-3 | Pembrolizumab increased total costs by $80,423 and provided gains of 1.17 quality-adjusted life years (QALYs) and 1.24 life years (LYs) over lifetime. | Source → |
| Re-sensitizing Prostate Cancer to Treatment with a New Approach | Prostate Cancer | phase-1 | — | Source → |
| Tumor Burden Predicts Survival in Lung Cancer Patients | Lung Cancer | phase-2 | Tumor burden below the baseline burden throughout therapy was associated with a median OS of 26.8 months, compared to 7.6 months for those with an increase in tumor burden. | Source → |
| Melanoma Patients' Outcomes After Failed Anti-PD-1 Therapy | Melanoma | observational | The overall response rate to BRAF/MEKi was 75%, 3/4. | Source → |
| Pembrolizumab Monotherapy in Triple-Negative Breast Cancer: Biomarkers for Response | Breast Cancer | phase-2 | — | Source → |
| Rare Side Effect of Cancer Treatment: Immune-Mediated Gastritis | Lung Cancer | observational | — | Source → |
| Pembrolizumab Cost-Effectiveness in Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Pembrolizumab treatment in older patients with mismatch repair-deficient colorectal cancer | Colorectal Cancer | observational | Median progression-free survival was 21 months. | Source → |
| New Cancer Treatment Shows Promise in Resistant Melanoma | Melanoma | phase-1/2 | — | Source → |
| Antibodies in Cancer Patients May Affect Treatment with Pembrolizumab | Melanoma | lab-study | Those melanoma patients with the highest levels (>75% percentile, n = 5) of pembrolizumab-F(ab')2 reactive AHA had significantly better overall survival post pembrolizumab treatment (p = 0.039). | Source → |
| Pembrolizumab Effectiveness in Advanced Lung Cancer | Lung Cancer | meta-analysis | Pembrolizumab in combination with chemotherapy was superior to chemotherapy in terms of overall survival (HR=0.60, 95%CI:0.50-0.73), progression-free survival (HR=0.47, 95%CI:0.38-0.58), and objective response rate (OR=3.22, 95%CI:2.57-4.03). | Source → |
| Rare Cancer Patient Shows Response to Immunotherapy | Melanoma | observational | — | Source → |
| Pembrolizumab treatment shows promise for some lung cancer patients | Lung Cancer | observational | — | Source → |
| Detecting Cancer Cells in Blood May Help Guide Treatment for Some Breast Cancer Patients | Breast Cancer | phase-2 | — | Source → |
| Combination Cancer Treatment Tested in Japanese Patients | Lung Cancer | phase-1 | The objective response rate was 33.3%. | Source → |
| Pembrolizumab Improves Survival in Melanoma Patients | Melanoma | phase-3 | Pembrolizumab significantly improved distant metastasis-free survival (hazard ratio [HR] 0·64, 95% CI 0·47-0·88, p=0·0029) versus placebo. | Source → |
| Pembrolizumab Therapy Shows Promise for Advanced Colorectal Cancer | Colorectal Cancer | observational | The lymph nodes reduced markedly after the therapy. | Source → |
| Rare kidney problem linked to cancer treatment | Lung Cancer | observational | — | Source → |
| Pembrolizumab Effectiveness and Safety in Japanese Melanoma Patients | Melanoma | observational | The overall objective response rate was 16.5% at the 1-year follow-up. | Source → |
| Rare Skin Reaction Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Combining Lenvatinib and Pembrolizumab for Advanced Melanoma | Melanoma | phase-2 | The overall response rate was 21.4% in the total population, with 33.3% in patients who had previously received anti-PD-1 plus anti-CTLA-4 therapy. | Source → |
| Using Computer Models to Improve Cancer Drug Research | Lung Cancer | review | — | Source → |
| Pembrolizumab treatment for elderly lung cancer patients | Lung Cancer | phase-2 | The median progression-free survival was 9.6 months. | Source → |
| Rare Blood Cancer Linked to Immunotherapy Treatment | Leukemia | observational | — | Source → |
| Rare Brain Infection Found in Cancer Patient on New Treatment | Lung Cancer | observational | — | Source → |
| Pembrolizumab Improves Outcomes in Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Monitoring Cancer Treatment with PET Scans | Breast Cancer | observational | — | Source → |
| Rare Neurotoxicity Side Effect of Cancer Treatment | Lung Cancer | observational | — | Source → |
| Pembrolizumab vs. Chemotherapy for Esophageal Cancer: Cost-Effectiveness Study | Leukemia | phase-3 | — | Source → |
| Combining Pembrolizumab with microRNA-20b-5p May Improve Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Pembrolizumab Monotherapy for Lung Cancer in Elderly or Those with Poor Health | Lung Cancer | observational | The median progression-free survival was 4.4 months for patients with poor health and 5.3 months for those aged 75 or older. | Source → |
| Woman develops rare condition after cancer treatment | Lung Cancer | observational | — | Source → |
| Tumour size linked to survival in lung cancer patients treated with pembrolizumab | Lung Cancer | phase-3 | The median overall survival was 18.2 months for patients with tumours larger than 86 mm, versus not reached for those with tumours 86 mm or smaller. | Source → |
| Rare Kidney Problem Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
| Researchers Report Pathological Complete Response to Pembrolizumab in Colon Cancer Patient | Colorectal Cancer | observational | — | Source → |
| Melanoma Treatment: New Options After Pembrolizumab | Melanoma | phase-3 | The overall response rate with subsequent ipilimumab was 17.5% and 30.5% with BRAF ± MEKi. | Source → |
| Combination Therapy Shows Promise in Advanced Melanoma | Melanoma | phase-2 | ORR was 55% in PEM200+IPI50; 61% in PEM200+IPI100. | Source → |
| Combination Therapy Shows Promise for Rare Lung Cancer in Young Patients | Lung Cancer | phase-2 | — | Source → |
| New Test for Lung Cancer Patients on Immunotherapy | Lung Cancer | lab-study | Patients with unfavourable changes in the hTERT cfDNA levels from baseline to 12 weeks showed a higher risk of disease progression. | Source → |
| Comparing Two Treatment Sequences for Advanced Lung Cancer | Lung Cancer | phase-2 | The objective response rate at 24 weeks in both arms was 39.5% and 40.4%, respectively. | Source → |
| Rare Skin Reaction Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Pembrolizumab Monotherapy Improves Outcomes in Lung Cancer Patients | Lung Cancer | phase-3 | Pembrolizumab improved overall survival versus chemotherapy in patients with or without baseline brain metastases: benefit was seen in patients with PD-L1 TPS ≥50% (0.67 [95% confidence intervals (CI): 0.44‒1.02] and 0.66 [95% CI: 0.58‒0.76], respectively) and PD-L1 TPS ≥1% (0.83 [95% CI: 0.62‒1.10] and 0.78 [95% CI: 0.71‒0.85], respectively). | Source → |
| Pembrolizumab with Chemotherapy in Colorectal Cancer | Colorectal Cancer | phase-2 | The primary endpoint of progression-free survival at 10 months is expected to be greater than 50%, but a 70% rate is hoped for. | Source → |
| New Way to Predict Lung Cancer Treatment Success | Lung Cancer | lab-study | Increased richness during treatment was associated with durable clinical benefit (p = 0.046), longer progression-free survival (p = 0.007) and overall survival (p = 0.05). | Source → |
| New Tool Helps Predict Lung Cancer Progression in Patients Treated with Pembrolizumab | Lung Cancer | observational | — | Source → |
| Combining Immunotherapy for Melanoma After Treatment Failure | Melanoma | phase-2 | The irRECIST response rate was 29% among the entire trial population. | Source → |
| Pembrolizumab Improves Survival in Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | Median progression-free survival was 16.5 months for pembrolizumab versus 8.2 months for standard treatment. | Source → |
| Early PET Scan Results Predict Long-Term Outcome in Melanoma Patients | Melanoma | observational | — | Source → |
| Pembrolizumab Improves Quality of Life for Colorectal Cancer Patients | Colorectal Cancer | phase-3 | Least squares mean change from baseline to prespecified week 18 showed a clinically meaningful improvement in EORTC QLQ-C30 GHS/QOL scores with pembrolizumab versus chemotherapy (between-group LSM difference 8·96 [95% CI 4·24-13·69]; two-sided nominal p=0·0002). | Source → |
| Pembrolizumab Treatment Affects T Lymphocyte Subsets in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Rare Pancreatic Cancer Responds to Immunotherapy | Pancreatic Cancer | observational | — | Source → |
| Pembrolizumab's Effectiveness and Safety in Treating Melanoma | Melanoma | review | — | Source → |
| Rare Eye Problem in Cancer Patient on New Treatment | Lung Cancer | observational | — | Source → |
| Pembrolizumab treatment stabilizes anaplastic oligodendroglioma in rare case | Leukemia | observational | — | Source → |
| Pembrolizumab dosing patterns in melanoma and lung cancer | Melanoma | observational | — | Source → |
| Pembrolizumab Before Surgery for Lung Cancer: Early Results | Lung Cancer | phase-2 | Four patients (27%) presented a major pathologic response. | Source → |
| Rare Kidney Damage Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Rare Eye Inflammation Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Rare Side Effect of Cancer Treatment: Bile Duct Damage | Lung Cancer | observational | — | Source → |
| Resuming Cancer Treatment After TB Infection | Lung Cancer | observational | — | Source → |
| Long-term Safety of Pembrolizumab in Advanced Melanoma | Melanoma | phase-3 | Patients who developed immune-related side effects had similar objective response rates (64.6% versus 63.0%) and median progression-free survival (17.0 versus 17.7 months) compared to those who did not. | Source → |
| Pembrolizumab and chemotherapy improve cancer treatment for some patients | Breast Cancer | phase-3 | — | Source → |
| Combining Quavonlimab and Pembrolizumab in Lung Cancer Treatment | Lung Cancer | phase-1 | Objective response rates were 40.0% in patients receiving quavonlimab 25 mg Q3W plus pembrolizumab, 37.5% in those receiving quavonlimab 25 mg Q6W plus pembrolizumab, 27.5% in those receiving quavonlimab 75 mg Q6W plus pembrolizumab, and 35.7% in those receiving quavonlimab 75 mg Q3W plus pembrolizumab. | Source → |
| Pembrolizumab and other drugs improve cancer outcomes in melanoma patients | Melanoma | phase-2 | Median progression-free survival was 16.9 months with the combination of pembrolizumab, dabrafenib, and trametinib, compared to 10.7 months with dabrafenib and trametinib alone. | Source → |
| Pembrolizumab-based therapy for lung cancer with brain metastases | Lung Cancer | observational | Intracranial ORR was 36.4% in patients with untreated BM. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.